Jakarta, April 10, 2026. As part of the Bio Farma Group, Kimia Farma views cross-sector collaboration, particularly with the Ministry of Foreign Affairs, as a crucial step in opening international market access. This commitment was reflected in the Production Facility Visit and Pharmaceutical Sector Health Diplomacy Dialogue held on April 9–10, 2026, at Kimia Farma and Bio Farma's production facilities.
This event was also attended by the Head of the Center for Asia Pacific and Africa Regional Policy Strategy, Ministry of Foreign Affairs of the Republic of Indonesia, Vahd Nabyl A. Mulachela, and was part of an effort to strengthen synergy between the government and state-owned pharmaceutical companies to open wider opportunities for national pharmaceutical products in the international market.
Hanadi Setiarto, Commercial Director of Kimia Farma, stated that the synergy between Bio Farma Group and the Ministry of Foreign Affairs is a crucial step in expanding market access and strengthening Indonesia's position in global health diplomacy.
"This agenda represents a strategic momentum to expand global market access and strengthen Indonesia's role in health diplomacy. We continue to improve production quality and capacity to be competitive internationally," said Hanadi.
Meanwhile, Bio Farma's Director of Finance and Risk Management, Jeffri Susanto, emphasized that the holding company's role is a crucial element in strengthening the Bio Farma Group's integration and competitiveness.
"As a single ecosystem, Bio Farma Group possesses complementary synergistic strengths, from development and production to distribution. This integration is crucial for enhancing the competitiveness of the national pharmaceutical industry, strengthening health resilience, and supporting Indonesia's increasingly active role in the global healthcare market," said Jeffri.
This activity also reaffirmed Bio Farma Group's commitment to continuously strengthening strategic collaboration across sectors and countries, enhancing product competitiveness, and optimizing health diplomacy as a key enabler in developing the national pharmaceutical export market.
Through ongoing synergy between Bio Farma Group and the government, it is hoped that the national pharmaceutical industry can increasingly play a role in strengthening Indonesia's position as a trusted global healthcare partner, while simultaneously encouraging the growth of a competitive and sustainable national healthcare industry.